Jessica Donington, MD / Jonathan D. Spicer, MD, PhD, FRCSC - A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.

A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Jessica Donington, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.

Co-Chair/Planner
Jonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.

Faculty/Planner
Patrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.